Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure.

"Declaration of personal interests : Florence Wong reports grants and personal fees from Mallinckrodt Pharmaceuticals and Sequana Medical; and personal fees from Ocelot Bio and River 2 Renal. S Chris Pappas reports personal fees from Durect, Exelixis, HepQuant, Mallinckrodt Pharmaceuticals, and Orphan Therapeutics LLC. K Rajender Reddy reports grants from AbbVie, BMS, Conatus, Exact Sciences, Gilead, Grifols, HCC‐TARGET, HCV‐TARGET, Intercept, Merck, NASH‐TARGET, Mallinckrodt Pharmaceuticals; and personal fees from AbbVie, BMS, Dova, Gilead, Merck, Shionogi, Spark Therapeutics. Hugo Vargas reports grants and other from Mallinckrodt Pharmaceuticals. Michael Curry reports personal fees from Mallinckrodt Pharmaceuticals; and grants from Gilead, Mallinckrodt Pharmaceuticals, and Sonic Incytes. Arun Sanyal holds stock options in Durect, Exhalenz, Genfit, Hemoshear, Indalo, Rivus, Sanyal Bio, and Tiziana; has received paid consulting advisor fees from Albireo, Amgen, Boehringer Ingelheim, Bristol Myers Squibb, Conatus, Covance, Eli Lilly, Genentech, Genfit, Gilead, Hemoshear, HistoIndex, Inventiva, Janssen Pharmaceuticals, Mallinckrodt Pharmaceuticals, Madrigal, Merck, NGM Bio, Northsea, Novartis, Novo Nordisk, Path AI, Pfizer, Poxel, Prosciento, Regeneron, Roche, Salix, Sanofi, Siemens, Takeda, Terns, and 89 Bio; is a non‐paid consultant for Amra, Biocellvia, Galectin, Fractyl, Immunron, Intercept, and Perspectum; provided consultant advice for AstraZeneca, for which renumeration was paid to Virginia Commonwealth University; was a member of a Data and Safety Monitoring Board for a study funded by Sequana; has received research grants from Boehringer Ingelheim, Bristol Myers Squibb, Conatus, Covance, Eli Lilly, Fractyl, Gilead, Inventiva, Madrigal, Mallinckrodt Pharmaceuticals, Merck, Novartis, and Novo Nordisk; has an ongoing research collaboration without direct funding with Echosense‐Sandhill, Owl, Second Genome, and Siemens; received study drug for the National Institute on Alcohol Abuse and Alcoholism (NIAAA) trial of Imm124 for patients with alcoholic hepatitis from Immuron, without funding; and has received royalties from Elsevier and UpToDate. Khurram Jamil is an employee of Mallinckrodt Pharmaceuticals. All authors have approved the final version of the manuscript. There was no writing support provided for this manuscript."

"FUNDING INFORMATION This manuscript was funded by Mallinckrodt Pharmaceuticals."